AJ Lanigan: Indeed. In Truth, pharma companies are building major dollars with therapies like Keytruda and Opdivo that deal with PD-one and PD-L1. Here’s the super cool section: consider checkpoints as targeted visitors signals. You don’t want an immune method that’s operating wild like a freight coach around a cliff. waiting for link from Social Bookmarking (3)